Interleaved 1H/23Na imaging for invasive and proliferative phenotypes of brain tumors
用于脑肿瘤侵袭性和增殖表型的交错 1H/23Na 成像
基本信息
- 批准号:10634269
- 负责人:
- 金额:$ 57.29万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-03-08 至 2027-02-28
- 项目状态:未结题
- 来源:
- 关键词:AcidityAdjuvant ChemotherapyAdjuvant TherapyBiological MarkersBrain NeoplasmsCell ProliferationCell SurvivalCell membraneCell physiologyCellsChemotherapy and/or radiationClinicalComputer softwareDataDiagnosisDiffuseElectrolytesGadoliniumGlioblastomaGoalsHistologyHumanImageImaging technologyImmuneImmunotherapyIndividualInductively Coupled Plasma Mass SpectrometryInfusion proceduresInjectionsIntercellular FluidIntracellular SpaceInvadedIonsLanthanoid Series ElementsLeadLibrariesMagnetic Resonance ImagingMalignant GliomaMalignant NeoplasmsMapsMembraneModelingModificationNHE1Normal CellOperative Surgical ProceduresOutcomePatientsPatternPhenotypePreclinical Drug DevelopmentPrognosisProliferatingProtonsRecurrenceResearchSalineSamplingScanningShapesSodium-Hydrogen AntiporterSystemTechnologyTestingTissuesUp-RegulationWorkcancer cellcancer therapycariporidechemical propertychemotherapyclinically relevantelectrical propertyimaging modalityimprovedinhibitorinterstitialmagnetic resonance spectroscopic imagingnovelpatient derived xenograft modelpreservationpublic health relevanceradio frequencysingle-cell RNA sequencingsodium ionspatiotemporalspectroscopic imagingstandard of caretemozolomidetranslational approachtumortumor growthtumor microenvironment
项目摘要
Invasive and proliferative phenotypes are vital cancer hallmarks, and these phenotypes are distinguished
by the fact that invasive cells lead the path for dividing cells as the tumor grows. Glioblastoma multiforme
(GBM) treatments, specifically chemotherapies, fail because cancer cells invade and proliferate beyond tumor
boundaries. But neither phenotypes can be tracked with existing imaging methods. We will develop 1H/23Na
MRSI technology to differentiate and track these phenotypes, and which will have major clinical relevance.
Compared to normal cells, cancer cells possess unique chemical and electrical properties. Interstitial fluid's
acidity and salinity are crucial for cell survival. Many cellular mechanisms help regulate essential cellular
functions by maintaining hydrogen ions (H+) and sodium ions (Na+) in the interstitial milieu, which is saline and
near neutral pH. Research from us, and others, reveal that acidity and salinity of interstitial and intracellular
spaces are altered in cancer, e.g., sodium-hydrogen exchanger 1 (NHE1), which aids H+ efflux and Na+ influx,
is upregulated in GBMs and contributes to altered transmembrane ion distributions.
Research on GBM models reveals an acidic interstitial fluid, vital for reshaping the interstitial matrix for
cancer cell proliferation and to guide cancer cell invasion. Similar work on human-derived GBMs shows that
interstitial Na+ is also altered, but this change supports a depolarized cell membrane - vital for cancer cell
proliferation. These novel results suggest that the combination of interstitial pH (pHo) and transmembrane Na+
gradient (?Na+m) maps can help generate independent biomarkers of invasive and proliferative phenotypes.
While 1H-MRI with gadolinium agents tracks tumor size, we and others have shown that agents with other
lanthanides can be used for pHo mapping with 1H-MRSI and ?Na+m mapping with 23Na-MRSI. These 1H/23Na
maps are currently obtained individually, requiring lengthy acquisitions with separate agent injections. To
explore the relationship between dysregulated pH and electrolyte imbalances regulating cancer cell invasion
and proliferation, pHo and ?Na+m maps must be spatiotemporally compared during tumor growth/therapy.
Our goal is to test the hypothesis that invasive cells lead dividing cells as the tumor grows, and explore
how their patterns change with treatment. First, we will interleave 1H and 23Na acquisitions to enable rapid pHo
and ?Na+m mapping with a single agent infusion. Next, proliferative and invasive maps from combination of pHo
and ?Na+m maps will be validated in nodular vs. invasive patient -derived xenografts (PDXs) using IHC and
ICP-MS. For clinical relevance, we will test potential of NHE1 inhibitor as an adjuvant chemotherapy to improve
GBM outcome. We will compare pHo and ?Na+m maps with two different therapies (i.e., first-line GBM standard
of care chemotherapy temozolomide alone vs. temozolomide + cariporide) to capture fates of invasive and
proliferative phenotypes in nodular vs. invasive PDXs.
侵袭性和增殖性表型是重要的癌症标志,这些表型是不同的。
这是因为当肿瘤生长时,侵入性细胞会引导细胞分裂。多形性胶质母细胞瘤
(GBM)治疗,特别是化疗,失败是因为癌细胞侵入并增殖到肿瘤之外,
边界但这两种表型都不能用现有的成像方法进行跟踪。我们将开发1H/23Na
MRSI技术,以区分和跟踪这些表型,这将有重大的临床意义。
与正常细胞相比,癌细胞具有独特的化学和电学性质。间质液
酸度和盐度对细胞生存至关重要。许多细胞机制有助于调节细胞的基本功能
通过维持间质环境中的氢离子(H+)和钠离子(Na+)起作用,间质环境是盐水,
我们和其他人的研究表明,间质和细胞内的酸度和盐度
在癌症中,例如,钠-氢交换器1(NHE 1),其有助于H+流出和Na+流入,
在GBM中上调并有助于改变跨膜离子分布。
对GBM模型的研究揭示了一种酸性间质液,对于重塑间质基质至关重要,
癌细胞增殖和引导癌细胞侵袭。对人类GBM的类似研究表明,
间质Na+也改变,但这种改变支持去极化细胞膜-对癌细胞至关重要
增殖这些新的结果表明,间质pH值(pHo)和跨膜Na+的组合
梯度(?Na + m)图谱可以帮助生成侵袭性和增殖性表型的独立生物标志物。
虽然使用钆剂的1H-MRI跟踪肿瘤大小,但我们和其他人已经表明,使用其他药物的药物也可以跟踪肿瘤大小。
镧系元素可用于pHo作图与1H-MRSI和?使用23Na-MRSI进行Na + m标测。1H/23Na
目前,图是单独获得的,需要通过单独的试剂注入进行长时间的采集。到
探讨pH失调与电解质失衡调节癌细胞侵袭之间的关系
和增殖,pHo和?在肿瘤生长/治疗期间,必须对Na + m图进行时空比较。
我们的目标是检验侵袭性细胞在肿瘤生长时引导分裂细胞的假设,并探索
他们的模式如何随着治疗而改变。首先,我们将交错1H和23 Na采集,以实现快速pHo
然后呢?单剂输注的Na + m标测。接下来,根据pHo和pH2的组合,
然后呢?Na + m图谱将在结节性vs.侵袭性患者来源的异种移植物(PDX)中使用IHC进行验证,
对于临床相关性,我们将测试NHE 1抑制剂作为辅助化疗以改善患者的免疫功能的潜力。
GBM结果。我们将比较pH值和?两种不同疗法的Na + m图(即,一线GBM标准
单独替莫唑胺与替莫唑胺+Cariporide),以捕获侵袭性和
结节性与侵袭性PDX的增殖表型。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Dewan Syed Fahmeed Hyder其他文献
Dewan Syed Fahmeed Hyder的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Dewan Syed Fahmeed Hyder', 18)}}的其他基金
Acquisition of a Bruker 11.7T/16cm Preclinical Scanner for Novel MRI/MRSI Studies
采购布鲁克 11.7T/16cm 临床前扫描仪用于新型 MRI/MRSI 研究
- 批准号:
10630511 - 财政年份:2023
- 资助金额:
$ 57.29万 - 项目类别:
Hypoxia and pH Responsive Nanoparticles for Targeted Drug Delivery to Ischemic Stroke
用于缺血性中风靶向药物输送的缺氧和 pH 响应纳米颗粒
- 批准号:
10681846 - 财政年份:2023
- 资助金额:
$ 57.29万 - 项目类别:
Metabolic and neuromodulatory basis of altered activated and deactivated cortical areas in healthy human aging
健康人类衰老过程中激活和失活皮质区域改变的代谢和神经调节基础
- 批准号:
10647162 - 财政年份:2022
- 资助金额:
$ 57.29万 - 项目类别:
Delayed white matter loss in concussive head injuries and its treatment
颅脑震荡迟发性脑白质丢失及其治疗
- 批准号:
10532800 - 财政年份:2021
- 资助金额:
$ 57.29万 - 项目类别:
Delayed white matter loss in concussive head injuries and its treatment
颅脑震荡迟发性脑白质丢失及其治疗
- 批准号:
10354469 - 财政年份:2021
- 资助金额:
$ 57.29万 - 项目类别:
MRS validation of computational metabolic modeling of human brain function to determine energetic disruptions underlying fMRI-derived functional connectivity in degenerative or psychiatric disorders
MRS 验证人脑功能的计算代谢模型,以确定退行性或精神疾病中 fMRI 衍生的功能连接潜在的能量破坏
- 批准号:
9246003 - 财政年份:2017
- 资助金额:
$ 57.29万 - 项目类别:
Multivalent PARACEST agents for quantitative molecular imaging
用于定量分子成像的多价 PARACEST 试剂
- 批准号:
8470166 - 财政年份:2010
- 资助金额:
$ 57.29万 - 项目类别:
Translation of smart contrast agents for brain tumor characterization by MR
MR 脑肿瘤表征智能造影剂的转化
- 批准号:
8408792 - 财政年份:2010
- 资助金额:
$ 57.29万 - 项目类别:
Multivalent PARACEST agents for quantitative molecular imaging
用于定量分子成像的多价 PARACEST 试剂
- 批准号:
8101171 - 财政年份:2010
- 资助金额:
$ 57.29万 - 项目类别:
Multivalent PARACEST agents for quantitative molecular imaging
用于定量分子成像的多价 PARACEST 试剂
- 批准号:
8281539 - 财政年份:2010
- 资助金额:
$ 57.29万 - 项目类别:
相似海外基金
3D Engineered Model of Microscopic Colorectal Cancer Liver Metastasis for Adjuvant Chemotherapy Screens
用于辅助化疗筛选的显微结直肠癌肝转移 3D 工程模型
- 批准号:
10556192 - 财政年份:2023
- 资助金额:
$ 57.29万 - 项目类别:
Developing Digital Pathology Biomarkers for Response to Neoadjuvant and Adjuvant Chemotherapy in Breast Cancer
开发数字病理学生物标志物以应对乳腺癌新辅助和辅助化疗
- 批准号:
10315227 - 财政年份:2021
- 资助金额:
$ 57.29万 - 项目类别:
Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Stage III Colorectal Cancer: A Multicentre Phase II/III Randomised Controlled Trial (DYNAMIC-III)
循环肿瘤 DNA 分析为 III 期结直肠癌辅助化疗提供信息:多中心 II/III 期随机对照试验 (DYNAMIC-III)
- 批准号:
443988 - 财政年份:2021
- 资助金额:
$ 57.29万 - 项目类别:
Operating Grants
Establishment of new selection system for adjuvant chemotherapy of colorectal cancer
结直肠癌辅助化疗新选择体系的建立
- 批准号:
20K09011 - 财政年份:2020
- 资助金额:
$ 57.29万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improved survival by Helicobacter pylori-modulated immunity in gastric cancer patients with adjuvant chemotherapy
幽门螺杆菌调节免疫力可改善接受辅助化疗的胃癌患者的生存率
- 批准号:
19K09130 - 财政年份:2019
- 资助金额:
$ 57.29万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
A new strategy of adjuvant chemotherapy for lung cancer based on the expression of anti-aging gene Klotho
基于抗衰老基因Klotho表达的肺癌辅助化疗新策略
- 批准号:
19K18225 - 财政年份:2019
- 资助金额:
$ 57.29万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Novel candidate factors predicting the effect of S-1 adjuvant chemotherapy of pancreatic cancer
预测胰腺癌S-1辅助化疗效果的新候选因素
- 批准号:
18K16337 - 财政年份:2018
- 资助金额:
$ 57.29万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Project 2-Metabolic Modulation of Myeloid-Derived Suppressor Cells to Increase Efficacy of Neo adjuvant Chemotherapy and Immunotherapy
项目2-骨髓源性抑制细胞的代谢调节以提高新辅助化疗和免疫疗法的疗效
- 批准号:
10005254 - 财政年份:2018
- 资助金额:
$ 57.29万 - 项目类别:
Radiogenomic tools for prediction of breast cancer neo-adjuvant chemotherapy response from pre-treatment MRI
通过治疗前 MRI 预测乳腺癌新辅助化疗反应的放射基因组学工具
- 批准号:
9763320 - 财政年份:2018
- 资助金额:
$ 57.29万 - 项目类别:
Analysis of the molecular mechanism for the prognostic biomarker of adjuvant chemotherapy
辅助化疗预后生物标志物的分子机制分析
- 批准号:
18K07341 - 财政年份:2018
- 资助金额:
$ 57.29万 - 项目类别:
Grant-in-Aid for Scientific Research (C)